Abstract
Many patients with severe asthma have mixed phenotypes, with eligibility for anti-eosinophilic or anti-immunoglobulin E (IgE) biologics (eg, omalizumab). Here, we assess the impact of baseline total IgE (tIgE) and history of previous omalizumab use on real-world outcomes in patients with severe asthma selected to receive mepolizumab therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
